Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

BioDelivery (BDSI) Q1 Earnings Beat Estimates, Stock Gains

Published 05/15/2017, 10:21 PM
Updated 07/09/2023, 06:31 AM

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) reported earnings of 58 cents per share in the first quarter of 2017, which comfortably beat the Zacks Consensus Estimate of 9 cents. The company had reported loss of 36 cents per share in the year-ago quarter.

BioDelivery’s shares gained almost 5% in after-hours trading. In fact, shares have traded above the Zacks classified Medical-Biomed/Genetics industry so far this year. The stock gained 14.3%, while the industry registered an increase of 1.9%.



Revenues, on the other hand, were $29.5 million in the reported quarter compared with $3 million a year ago. Revenues also surpassed the Zacks Consensus Estimate of $27 million.

We remind investors that BioDelivery reacquired worldwide rights to Belbuca in Jan 2017 from Endo Pharmaceuticals, a subsidiary of Endo International Plc (NASDAQ:ENDP) . As a result of the reacquisition, the company started recording product revenues for Belbuca against royalties being recorded previously.

Higher Belbuca revenues resulted from recognition of deferred revenue associated with the license termination and reacquisition of Belbuca.

Quarter in Detail

BioDelivery’s opioid-dependence drug, Bunavail, recorded 52.4% year-over-year increase in sales to $3.2 million. The increase in revenues can be attributed to $1.7 million recognized as sales for product shipped to wholesalers before Jan 2017. The company said that it is working to secure new managed contracts for Bunavail.

In the reported quarter, the company recorded the highest net sales revenue of $4.6 million for Belbuca since the product was launched a year ago. The company said the drug generated sufficient product revenue to offset the expense of the commercial business unit.

In the first quarter, research and development expenses decreased 50% to $2.7 million from the year-ago figure of $5.4 million. Selling, general and administrative expenses were up 1.5% year over year to $13.3 million.

In the reported quarter, BioDelivery received approval from the FDA for a supplemental new drug application (sNDA) for the label expansion of Bunavail. The company is looking to expand the label of Bunavail to include induction of buprenorphine treatment for opoid dependence.

During the same period, the FDA accepted the investigational new drug (IND) for sustained release buprenorphine injection, allowing the company to start its clinical development program.

Zacks Rank & Key Picks

BioDelivery currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Aeglea BioTherapeutics (NASDAQ:AGLE) and VIVUS, Inc. (NASDAQ:VVUS) . While Aeglea carries a Zacks Rank #2 (Buy), VIVUS sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Aeglea’s loss per share estimates narrowed from $3.64 to $2.48 for 2017, over the last 60 days. The company posted positive earnings surprises in three of the four trailing quarters with an average beat of 20.75%.

VIVUS’s loss per share estimates narrowed from 50 cents to 39 cents for 2017, over the last 30 days. The company posted positive earnings surprises in all of the four trailing quarters with an average beat of 233.69%.

5 Trades Could Profit "Big-League" from Trump Policies

If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.

Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>



VIVUS, Inc. (VVUS): Free Stock Analysis Report

BioDelivery Sciences International, Inc. (BDSI): Free Stock Analysis Report

Aeglea BioTherapeutics, Inc. (AGLE): Free Stock Analysis Report

Endo International PLC (ENDP): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.